Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma

In 28 patients with neuroblastoma of different stages the karyotype was determined in the primary tumour and/or in the metastases by direct chromosome preparation or short term cell culture. In addition, DNA analysis for the proto-oncogene N-myc was performed for comparison in 10 cases. Abnormalities (deletions, translocations, derivations) of the short arm of chromosome 1 with the most frequent breakpoint at 1p32 (besides rarer aberrations in other chromosomes) were found in the tumour karyotype of 15 of 18 (83%) patients with metastatic disease (stage IV) and in 2 of 3 patients with stage III, but in none of the 7 patients with stages I, II, IV-S who are all alive with no evidence of disease. These 7 surviving patients with good prognosis had a hyperploid tumour karyotype, mainly in the triploid range. Eleven of the 18 (61%) patients with stage IV and 1 of 3 patients with stage III also contained double minutes (DMs) and/or homogeneously staining regions (HSRs) in their tumour karyotypes. N-myc amplification (30 to 60 copies) in the tumour DNA was detected in 2 of 6 (33%) examined cases with stage IV, in 1 out of 2 examined cases with stage III, and correlated with the presence of DMs/HSRs. Life table analysis showed a 90% probability of surviving in patients lacking the 1p abnormality as compared to less than 10% in patients with an aberrant 1p chromosome in the tumour cells. We conclude that tumour karyotype, in particular the structure of the short arm of chromosome 1, is the most important factor in determining the different outcome in children with neuroblastoma.

Abstract licence: CC BY

1. 1.

   Brodeur G. M., Green A. A., Hayes F. A., Williams K. J., Williams D. L., Tsiatis A. A. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 1981;41(11 Pt 1):4678-4686.

   Not in our library

2. 2.

   Brodeur G. M., Seeger R. C., Schwab M., Varmus H. E., Bishop J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121-1124.

   Not in our library10.1126/science.6719137 (opens in a new tab)

3. 3.

   Christiansen H., Franke F., Bartram C. R., Adolph S., Rudolph B., Harbott J., Reiter A., Lampert F. Evolution of tumor cytogenetic aberrations and N-myc oncogene amplification in a case of disseminated neuroblastoma. Cancer Genet Cytogenet. 1987;26(2):235-244.

   Not in our library10.1016/0165-4608(87)90057-4 (opens in a new tab)

4. 4.

   Evans A. E., D'Angio G. J., Propert K., Anderson J., Hann H. W. Prognostic factor in neuroblastoma. Cancer. 1987;59(11):1853-1859.

   Not in our library10.1002/1097-0142(19870601)59:11<1853::aid-cncr2820591102>3.0.co;2-f (opens in a new tab)

5. 5.

   Franke F., Förster W., Rudolph B., Lampert F. Metastatic neuroblastoma in an infant: translocation (1;11), deletion (2) and double minute chromosomes. Eur J Pediatr. 1985;143(4):305-308.

   Not in our library10.1007/bf00442308 (opens in a new tab)

6. 6.

   Franke F., Rudolph B., Christiansen H., Harbott J., Lampert F. Tumour karyotype may be important in the prognosis of human neuroblastoma. J Cancer Res Clin Oncol. 1986;111(3):266-272.

   Not in our library10.1007/bf00389243 (opens in a new tab)

7. 7.

   Franke F., Rudolph B., Lampert F. Translocation (19;?) in two stage II neuroblastomas. Cancer Genet Cytogenet. 1986;20(1-2):129-135.

   Not in our library10.1016/0165-4608(86)90116-0 (opens in a new tab)

8. 8.

   Gansler T., Chatten J., Varello M., Bunin G. R., Atkinson B. Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome. Cancer. 1986;58(11):2453-2458.

   Not in our library10.1002/1097-0142(19861201)58:11<2453::aid-cncr2820581117>3.0.co;2-i (opens in a new tab)

9. 9.

   Gilbert F., Feder M., Balaban G., Brangman D., Lurie D. K., Podolsky R., Rinaldt V., Vinikoor N., Weisband J. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 1984;44(11):5444-5449.

   Not in our library

10. 10.

    Hayashi Y., Habu Y., Fujii Y., Hanada R., Yamamoto K. Chromosome abnormalities in neuroblastomas found by VMA mass screening. Cancer Genet Cytogenet. 1986;22(4):363-364.

    Not in our library10.1016/0165-4608(86)90029-4 (opens in a new tab)

11. 11.

    Look A. T., Hayes F. A., Nitschke R., McWilliams N. B., Green A. A. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984;311(4):231-235.

    Not in our library10.1056/nejm198407263110405 (opens in a new tab)

12. 12.

    Rosen N., Reynolds C. P., Thiele C. J., Biedler J. L., Israel M. A. Increased N-myc expression following progressive growth of human neuroblastoma. Cancer Res. 1986;46(8):4139-4142.

    Not in our library

13. 13.

    Schwab M., Alitalo K., Klempnauer K. H., Varmus H. E., Bishop J. M., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983;305(5931):245-248.

    Not in our library10.1038/305245a0 (opens in a new tab)

• A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma · 2003

  Not checked

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.